• Forum
  • Premium
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • FemmeBreaking barriers and building confidence in investing
  • Learn about investing
    • Analysis SchoolLearn how to read and understand stock analysis
    • Investing SchoolGuides and lessons to grow your investing knowledge
    • Portfolio buildersInvesting knowledge for every level, from first steps to advanced portfolio strategies.
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Insider TransactionsTrack buying and selling activity by company insiders
    • Virtual Analyst ChatAsk questions and get instant AI-powered investment insights
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Log in to your Inderes Free account to see all free content on this page.
Create account

Cereno Scientific

4.62 SEK

+4.86 %

Less than 1K followers

CRNO B

First North Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Compare
+4.86 %
-16.83 %
-23.00 %
-33.96 %
-44.62 %
-57.02 %
+901.30 %
+32.26 %
-23.21 %

Cereno Scientific is a biotechnology company. The company specializes in drug development for common and rare cardiovascular diseases. The lead drug candidate is being developed for the treatment of the rare disease pulmonary arterial hypertension, as well as for thrombotic indications. In particular, epigenetic modulation is used to develop treatments for needy patients with cardiovascular diseases. Cereno Scientific's headquarters are located in Mölndal.

Read more
Market cap
1.44B SEK
Turnover
4.4M SEK
Revenue
EBIT %
P/E
Dividend yield-%
Revenue and EBIT-%
EPS and dividend
Financial calendar
All
Webcasts
Press releases
3rd party
ShowingAll content types

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
17.6.
2026

General meeting '26

26.8.
2026

Interim report Q2'26

4.11.
2026

Interim report Q3'26

Press release6/3/2026, 5:45 AM

Cereno Scientific to present at BIO International Convention 2026 and advance global partnering discussions

Cereno Scientific
Third party research5/27/2026, 6:49 AM

Cereno Scientific: Preclinical development for CS585 - Edison

Cereno Scientific has announced that its third asset, CS585 (a potent and selective agonist of the prostacyclin receptor), will be tested in preclinical disease model studies relating to antiphospholipid syndrome (APS), a rare autoimmune disease associated...

Cereno Scientific
Regulatory press release5/27/2026, 6:00 AM

Cereno Scientific Publishes Interim Report for Q1 2026

Cereno Scientific

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and deep analyses
Premium tools: model portfolio, screener, insider transactions
Premium columns: Guest column, expert insights
Inderes MCP - Inderes data directly into your AI tools
Create account
Press release5/26/2026, 5:45 AM

Cereno Scientific Confirms First Volunteer Dosed in CS014 PK-bridging Study Supporting Phase II Development in PH-ILD

Cereno Scientific
Regulatory press release5/22/2026, 5:24 PM

Cereno Scientific publishes Annual Report for 2025

Cereno Scientific
Press release5/21/2026, 5:45 AM

Cereno Scientific to Initiate Preclinical Evaluation of CS585 in Rare Disease Antiphospholipid Syndrome (APS) Progressing toward Clinical Phase

Cereno Scientific
Regulatory press release5/15/2026, 12:30 PM

Cereno Scientific give notice to attend the Annual General Meeting 2026

Cereno Scientific
Press release5/11/2026, 5:30 AM

Cereno Scientific Enters Collaboration with PHA Europe & Global to Advance Patient-centered Drug Development in Pulmonary Hypertension

Cereno Scientific
Press release4/10/2026, 6:45 AM

Cereno Scientific to Participate at Nordic Health Summit Japan and ChinaBio Partnering Forum 2026

Cereno Scientific
Press release4/4/2026, 6:00 AM

Cereno Scientific Highlights Strategic Value of Meeting Primary Endpoint of Safety and Tolerability of 12-month CS1 Data in PAH

Cereno Scientific
Regulatory press release3/31/2026, 5:30 AM

Cereno Scientific Reports Favorable Safety and Tolerability after 12 Months of CS1 Treatment in PAH from the Expanded Access Program

Cereno Scientific
Press release3/27/2026, 10:09 AM

Cereno Scientific: Stifel Initiates Coverage with Buy Rating and Price Target of SEK 20

Cereno Scientific
Third party research3/24/2026, 12:28 PM

Cereno Scientific: Inflection points coming into view - Edison

Cereno Scientific’s FY25 results mark a strategically productive period, with multiple value inflection points coming into focus in FY26. With the Phase IIb start for lead asset CS1 expected in Q226, we anticipate a step-up in clinical activity and partnering...

Cereno Scientific
Press release3/17/2026, 11:20 AM

Cereno Scientific Receives Approval to Initiate FDA-aligned Phase I Pharmacokinetic Study of CS014 Supporting Phase II Development in PH-ILD

Cereno Scientific
Press release3/12/2026, 6:45 AM

Cereno Scientific to Participate at BIO-Europe Spring and LSX World Congress Europe 2026 on March 23-26 in Lisbon

Cereno Scientific
Regulatory press release2/27/2026, 6:45 AM

Cereno Scientific Publishes Year-end Report for 2025 (January 1 - December 31, 2025)

Cereno Scientific
Third party research2/20/2026, 10:31 AM

Cereno Scientific: CMD reaffirms shifting focus to clinical delivery - Edison

Cereno Scientific’s recent capital markets day (CMD) centered on CS1’s progression from early clinical validation into Phase IIb development, a key inflection for the investment thesis. Supported by key opinion leader (KOL) and patient perspectives, ...

Cereno Scientific
Press release2/4/2026, 9:00 AM

Cereno Scientific broadens development focus for CS014 to pulmonary hypertension associated with interstitial lung disease

Cereno Scientific
Press release2/3/2026, 6:45 AM

Cereno Scientific Provides Update on Expanded Access Program for CS1 - initial learnings expected in Q1 2026

Cereno Scientific
Press release2/2/2026, 1:00 PM

Cereno Scientific Announces Program and Speakers for the Capital Markets Day on February 5, 2026

Cereno Scientific